NOTE FROM TED: Please do not look to this talk for medical or diagnostic advice and always consult a medical professional. This talk only represents the speaker's personal views and understanding of AI models and healthcare which warrants further scientific investigation. TEDx events are independently organized by volunteers. The guidelines we give TEDx organizers are described in more detail here: http://storage.ted.com/tedx/manuals/tedx_content_guidelines.pdf Why does modern medicine still miss so many di ...

Core Insights - Myriad Genetics reported fourth quarter revenue of approximately $210 million, exceeding the high end of its pre-announced range, with overall test volumes increasing by 2% year-over-year and underlying revenue growth of 4% after adjusting for an $8.1 million headwind from UnitedHealthcare's GeneSight coverage policy [3][7][2] Financial Performance - The company achieved consolidated revenue of $209.8 million, consistent with the previous year, and delivered 382,000 test results in the quarter [3][7] - Adjusted EBITDA for the quarter was reported at $14.3 million, with adjusted operating cash flow of $17.9 million and adjusted EPS of $0.04 [13] - Fourth quarter gross margin was 70%, down approximately 190 basis points year-over-year, attributed to the GeneSight revenue headwind [12] Segment Performance - In oncology, revenue reached $84.7 million, reflecting a 2% increase year-over-year, with MyRisk showing 14% volume growth in the affected market and 11% in the unaffected market [8][9] - Prolaris revenue growth accelerated to 16% year-over-year, driven by 12% volume growth, with investments in commercial channels to regain market share [9] - Women's health revenue was reported at $88.5 million, up 2% year-over-year, with hereditary cancer testing showing 3% revenue growth and 11% volume growth [9] Product Launches and Future Guidance - The company reaffirmed its full-year 2026 guidance of $860–880 million in revenue, with an adjusted gross margin of 68–69% and adjusted EBITDA of $37–49 million [5][14] - Myriad plans to launch an AI-enhanced Prolaris test in Q2 2026 and a full commercial launch of FirstGene prenatal screening in H2 2026 [6][15] - Management is reorganizing reporting into three strategic areas: cancer care continuum, prenatal health, and mental health, with a dedicated prenatal sales team [5][16] Operational Updates - Prenatal testing volumes declined year-over-year due to disruptions from a new test ordering system, but management is in an "active rebuild phase" to reactivate accounts and expand access [10] - GeneSight revenue for the fourth quarter was $36.6 million, supported by 9% year-over-year volume growth, with an expanded provider base of over 38,000 clinicians [11]

iRhythm Technologies (NasdaqGS:IRTC) FY Conference Summary Company Overview - **Company**: iRhythm Technologies - **Industry**: MedTech, specifically in cardiac monitoring and arrhythmia detection - **Conference Date**: January 12, 2026 Key Points and Arguments Financial Performance - iRhythm achieved over **$740 million** in revenue for 2025, exceeding guidance and marking the first profitable year in the company's history [10][35] - The company expects **$870-$880 million** in revenue for 2026, representing a growth of **17%-18%** [35] - For the first time, iRhythm will be **free cash flow positive** in 2025, with an expected **11.5%-12.5%** adjusted EBITDA margin for 2026 [35][36] Market Opportunity - There are **27 million undiagnosed individuals** with cardiac arrhythmias in the U.S., representing a significant market opportunity [5][11] - iRhythm currently holds **72% market share** in long-term cardiac monitoring (LTCM) and aims to expand its presence in the **Mobile Cardiac Telemetry (MCT)** space, where it has only **15% market share** [13][24] - The company is targeting a **30 million test** market opportunity, including both undiagnosed patients and international markets [12][13] Product and Technology - iRhythm's **Zio** monitoring system allows patients to wear a device for **14 days**, capturing nearly **1.5 million heartbeats** [8] - The company is developing a **third-generation algorithm** for arrhythmia detection, which is currently with the FDA [9] - iRhythm is leveraging **AI** to analyze **3 billion hours** of heartbeat data, enhancing predictive capabilities for undiagnosed arrhythmias [22][27] Strategic Initiatives - The company is focusing on expanding into **primary care**, with over **20% of prescribing** now coming from this channel [17] - iRhythm is collaborating with **innovative channel partners** to target comorbid disease states, which overlap significantly with arrhythmias [20] - The company is also exploring opportunities in adjacent markets such as **sleep apnea**, where there is a high correlation with arrhythmias [32][33] Competitive Landscape - iRhythm has a competitive advantage due to its established product in LTCM, while competitors primarily focus on MCT, making it difficult for them to penetrate the primary care market [52][53] - The company has been successful in integrating with **EHR systems**, which has led to a **20%-25% increase** in volume post-integration [30] Research and Evidence Generation - iRhythm has published over **135 research manuscripts**, with nearly **40 peer-reviewed**, establishing a strong evidence base for its products [11][12] - The company emphasizes the cost savings associated with early arrhythmia detection, estimating **$15-$17 million** in savings for every **1,000 patients** identified [32] Future Outlook - iRhythm is optimistic about its growth trajectory, with plans to continue investing in technology and market expansion while maintaining profitability [36][59] - The company aims to achieve **15% adjusted EBITDA margins** as it approaches **$1 billion** in revenue [37] Additional Important Insights - The company is addressing **capacity constraints** in the healthcare system by moving monitoring to primary care, where there is a significant shortage of cardiologists [6][17] - iRhythm's proactive approach to identifying undiagnosed patients through AI and data analysis is seen as a game changer in the industry [23][27] - The company is currently working on enhancing its MCT product to meet market demands for longer monitoring durations [24][46] This summary encapsulates the key points discussed during the iRhythm Technologies FY Conference, highlighting the company's financial performance, market opportunities, product innovations, strategic initiatives, competitive landscape, and future outlook.